Patients inspire us to bring them value through more cutting-edge science, more innovative drugs, and more practical solutions – so that they, and their carers, can get on with their lives. We focus on neurology and immunology disorders – putting patients at the center of our world.
Our high rate of investment in pioneering science, backed by a strong alliance with professional partners, allows us to bring our neurology and immunology drugs to hundreds of new patients every day across the globe.
Our growth will come from ground-breaking science and from bringing added value to patients, as well as being the preferred partner to all our other stakeholders. It’s summed up by UCB’s twin motivations, Inspired by patients. Driven by science.
UCB Legal Notice and Privacy Policy: http://www.ucb.com/legal
If you would like to contact your local UCB office, please visit: http://www.ucb.com/worldwide.
Our high rate of investment in pioneering science, backed by a strong alliance with professional partners, allows us to bring our neurology and immunology drugs to hundreds of new patients every day across the globe.
Our growth will come from ground-breaking science and from bringing added value to patients, as well as being the preferred partner to all our other stakeholders. It’s summed up by UCB’s twin motivations, Inspired by patients. Driven by science.
UCB Legal Notice and Privacy Policy: http://www.ucb.com/legal
If you would like to contact your local UCB office, please visit: http://www.ucb.com/worldwide.
Location: Belgium, Brussels-Capital, Anderlecht
Employees: 5001-10000
Phone: +32 2 559 99 99
Founded date: 1928
Investors 3
| Date | Name | Website |
| 06.07.2021 | New Enterp... | nea.com |
| - | RA Capital... | racap.com |
| - | Lightstone... | lightstone... |
Mentions in press and media 12
| Date | Title | Description |
| 03.05.2025 | Zucara Therapeutics Secures $25 Million to Combat Diabetes Complications | Zucara Therapeutics is on a mission. The Toronto-based company is tackling a significant challenge in diabetes management: hypoglycemia. Recently, Zucara completed its Series B financing, raising a total of $25 million. This funding is a li... |
| 02.05.2025 | Zucara Therapeutics: $25 Million Series B Closed For Diabetes Life Sciences Platform | Zucara Therapeutics – a diabetes life sciences company developing ZT-01, which is the first once-daily therapeutic to prevent hypoglycemia (low blood glucose levels) in people with diabetes – announced that it has completed the second and f... |
| 10.10.2019 | UCB to acquire Ra Pharmaceuticals for $2.1B | Shares of Ra were up nearly 100 percent following the news, trading at $45.34 per share on the Nasdaq Thursday afternoon. Shares of UCB were up nearly 2 percent on the Brussels Stock Exchange. “Ra Pharma is an excellent strategic fit addres... |
| 16.07.2019 | RA Capital closes first venture capital fund on $300m | RA Capital has raised just over $300m in a ‘one-and-done’ final close for its first venture capital fund, RA Capital |
| 04.05.2017 | NEA’s Ed Mathers talks biopharma investment trends and why it’s worth sticking around | In a recent phone interview, Mathers discussed his investment principles ahead of a panel appearance at the upcoming MedCity INVEST conference, May 17-18 in Chicago. By way of background, NEA is one of the largest tech and healthcare ventur... |
| 27.10.2016 | GSK dumps a late-stage HIV drug; MIT offers support for tech start-ups; Ra Pharma closes flat after $92M IPO | Andrew Witty, GSK GlaxoSmithKline didn’t just kill losmapimod on Wednesday. The pharma giant was also forced to dump a late-stage HIV drug acquired from Bristol-Myers late last year in a $1.46 billion deal. Here’s the explan... |
| 24.07.2015 | Daily funding roundup - July 24, 2015 | Northleaf Venture Catalyst Fund closed $300M; Voxel8 received $12M; AdAgility raised $1.6M AdAgility, a provider of personalized, on-site and mobile, cross-selling solutions, raised $1.6 million to further accelerate its already impressive ... |
| 24.07.2015 | Ra Pharmaceuticals Raises $58.5M Series B Financing | Ra Pharmaceuticals, a Cambridge, MA-based developer of peptide chemistry platform to deliver drugs with specificity of antibodies coupled with the pharmacological properties of small molecules, completed a $58.5m Series B financing. The rou... |
| 24.05.2012 | EMC, Ember, Spindle, Yottaa, & More Boston-Area Deals | Share Share on Facebook Share on Twitter LinkedIn Email Reprints A bunch of small-ish deals (and some not so small) to catch up on from the past week… —Hopkinton, MA-based EMC (NYSE: EMC) has acquired Syncplicity for an undisclosed price. T... |
| - | UCB to acquire Ra Pharmaceuticals for $2.1B | A Belgian drugmaker is spending more than $2 billion to acquire a company developing a drug to treat several rare and serious diseases. Brussels-based UCB said on Thursday that it would acquire Cambridge, Massachusetts-based Ra Pharmaceutic... |
Show more